Share Email Print
cover

Proceedings Paper

Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides
Author(s): Kwang Poo Chang; Bala K. Kolli; Chia-Kwung Fan; Dennis K. P. Ng; Clarence T. T. Wong; Laura Manna; Raffaele Corso; Neng-Yao Shih; Robert Elliott; X. P. Jiang; Shin-Hong Shiao; Guo-Liang Fu
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn- and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.

Paper Details

Date Published: 8 February 2018
PDF: 15 pages
Proc. SPIE 10479, Light-Based Diagnosis and Treatment of Infectious Diseases, 1047912 (8 February 2018); doi: 10.1117/12.2281437
Show Author Affiliations
Kwang Poo Chang, Chicago Medical School, Rosalind Franklin Univ. of Medicine and Science (United States)
Bala K. Kolli, Chicago Medical School, Rosalind Franklin Univ. of Medicine and Science (United States)
Chia-Kwung Fan, Taipei Medical Univ. (Taiwan)
Dennis K. P. Ng, The Chinese Univ. of Hong Kong (Hong Kong, China)
Clarence T. T. Wong, The Chinese Univ. of Hong Kong (Hong Kong, China)
Laura Manna, Univ. degli Studi di Napoli Federico II (Italy)
Raffaele Corso, Univ. degli Studi di Napoli Federico II (Italy)
Neng-Yao Shih, National Institute of Cancer Research, National Health Research Institutes (Taiwan)
Robert Elliott, Elliott Mastology Ctr. (United States)
X. P. Jiang, Elliott Mastology Ctr. (United States)
Shin-Hong Shiao, National Taiwan Univ. College of Medicine (Taiwan)
Guo-Liang Fu, GeneFirst Ltd. (United Kingdom)


Published in SPIE Proceedings Vol. 10479:
Light-Based Diagnosis and Treatment of Infectious Diseases
Tianhong Dai, Editor(s)

© SPIE. Terms of Use
Back to Top